Free Trial

Climb Bio, Inc. (NASDAQ:CLYM) Receives Consensus Recommendation of "Buy" from Analysts

Climb Bio logo with Medical background

Key Points

  • Climb Bio, Inc. has received a consensus recommendation of "Buy" from seven brokerages, with an average price objective of $9.25 for the next 12 months.
  • Despite some changes in analyst ratings, including a downgrade to "sell" by Wall Street Zen, several institutional investors, such as AQR Capital and XTX Topco, have recently purchased shares in Climb Bio.
  • The company's stock is currently trading at $1.98, with a 12-month range of $1.05 to $5.47 and a negative PE ratio of -2.83.
  • MarketBeat previews the top five stocks to own by November 1st.

Shares of Climb Bio, Inc. (NASDAQ:CLYM - Get Free Report) have received a consensus recommendation of "Buy" from the seven brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $9.25.

CLYM has been the topic of several recent research reports. Wall Street Zen lowered Climb Bio from a "hold" rating to a "sell" rating in a research report on Sunday, September 28th. Oppenheimer initiated coverage on Climb Bio in a research report on Friday, June 6th. They issued an "outperform" rating and a $10.00 price objective on the stock. BTIG Research upped their price objective on Climb Bio from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Tuesday. Robert W. Baird initiated coverage on Climb Bio in a research report on Friday, August 15th. They issued an "outperform" rating and a $9.00 price objective on the stock. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Climb Bio in a research report on Saturday, September 27th.

Get Our Latest Research Report on CLYM

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CLYM. AQR Capital Management LLC purchased a new position in shares of Climb Bio during the 1st quarter valued at approximately $27,000. XTX Topco Ltd purchased a new position in shares of Climb Bio during the 1st quarter valued at approximately $34,000. Qube Research & Technologies Ltd purchased a new position in shares of Climb Bio during the 2nd quarter valued at approximately $43,000. Marshall Wace LLP purchased a new position in shares of Climb Bio during the 2nd quarter valued at approximately $46,000. Finally, Nuveen LLC purchased a new position in shares of Climb Bio during the 1st quarter valued at approximately $48,000. Hedge funds and other institutional investors own 69.76% of the company's stock.

Climb Bio Trading Down 2.9%

Shares of NASDAQ:CLYM opened at $1.98 on Friday. Climb Bio has a twelve month low of $1.05 and a twelve month high of $5.47. The company's 50 day moving average is $2.05 and its 200 day moving average is $1.54. The company has a market cap of $134.16 million, a PE ratio of -2.83 and a beta of -0.07.

Climb Bio (NASDAQ:CLYM - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.06. Equities research analysts predict that Climb Bio will post -1.57 earnings per share for the current fiscal year.

About Climb Bio

(Get Free Report)

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.

Recommended Stories

Analyst Recommendations for Climb Bio (NASDAQ:CLYM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Climb Bio Right Now?

Before you consider Climb Bio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.

While Climb Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.